BioView

BioView is a pioneering company focused on revolutionizing cancer patient assessments and outcomes through its advanced automated imaging and analysis solutions. Founded in 2000 and headquartered in the United States, the company's mission is to digitize and streamline analysis workflows in clinical and research laboratories dealing with cytology, cytogenetics, and pathology. Their industry-leading platforms, driven by Artificial intelligence, offer groundbreaking capabilities for fluorescent and bright-field-based applications. BioView's innovative solutions encompass a wide range of applications, including automated FISH Analysis for cancer and genetic abnormalities, automated whole slide imaging for digital pathology, and quantitative IHC scoring applications for nuclear and membrane staining. The company is also at the forefront of bringing liquid biopsy to clinical practice, with a focus on detecting, enumerating, and characterizing circulating tumor cells through their DeNovo system that sets new standards in speed, standardization, and sensitivity. One of BioView’s standout offerings is their New Generation Karyotyping (NGK) platform, which leverages deep learning to enhance technician efficiency and productivity, introducing unique supervisor monitoring tools and an ISCN results generator directly connected to an online supporting cytogenetics database. With a focus on the biotechnology and manufacturing industries, BioView continues to empower customers by providing offline analysis and web-based applications for collaboration and exploring new business opportunities. Currently, there is no public information available regarding their latest investment or investors.